Real-World Data on Adult T-Cell Leukemia/Lymphoma in Latin America: A Study From the Grupo de Estudio Latinoamericano de Linfoproliferativos.
Luis E Malpica-CastilloDaniel Y Enriquez-VeraDenisse Angélica Castro-UriolCamila PeñaHenry IdroboLorena FiadMaria PratesVictoria OteroMirna BiglioneMilagros AltamiranoGustavo Sandival-AmpueroUrsula Aviles-PerezKelly MezaLaura Aguirre-MartinezNancy CristaldoJuan L MaradeiLuciana GuanchialePablo SotoJose L ViñuelaMaría Elena CabreraSally Rose ParedesEloisa RivaMarcos Di StefanoAndrea NoboaJuan A ChoqueMyrna CandelariaAlana Von GlasenappFabiola Valvert GamboaMaria A Torres-VieraJorge J CastilloJuan Carlos RamosLuis VillelaBrady Ernesto Beltrán-GáratePublished in: JCO global oncology (2021)
This study confirms Latin American ATLL presents at a younger age and has a high incidence of lymphomatous type, low incidence of indolent subtypes, and worse survival rates as compared with Japanese patients. In aggressive ATLL, chemotherapy remains the preferred choice for lymphomatous favoring etoposide-based regimen (etoposide, cyclophosphamide, vincristine, doxorubicin, and prednisone), whereas AZT-IFN remains a good first-line option for acute subtype.
Keyphrases
- risk factors
- liver failure
- low dose
- immune response
- diffuse large b cell lymphoma
- drug delivery
- bone marrow
- high dose
- acute myeloid leukemia
- electronic health record
- locally advanced
- squamous cell carcinoma
- machine learning
- young adults
- radiation therapy
- decision making
- childhood cancer
- hodgkin lymphoma
- extracorporeal membrane oxygenation